BioSpace News Archive

EQRx , a company committed to developing and delivering important new medicines at lower prices, today announced two key leadership appointments to advance the company’s mission of remaking medicine. Jami Rubin joins as chief financial officer to guide the strategic financial direction of the Company, effective April 5.

Two-Year Results Demonstrating Long-Term Effectiveness of Aerin Medical’s VivAer ® Treatment of Nasal Obstruction Published in International Forum of Allergy &Rhinology Data shows in-office treatment of nasal valve collapse resulted in lasting improvement in symptoms and quality of life SUNNYVALE, Calif.--( BUSINESS WIRE )-- Aerin Medical today announced the publication of two-year results from a multi-center, prospective study that demonstra

Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), an Alvogen company, has announced the issuance of new shares through private placement

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Dr. Leila Alland and Mr. Donald Wuchterl as new independent members to its Board of Directors.

Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs and Neeraj Teotia has been named Chief Commercial Officer where he will have responsibility for marketing, sales, and health economics

Salarius Pharmaceuticals, Inc . (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts detailing research involving seclidemstat were accepted for poster presentations, with one abstract also selected for a poster discussion session, at the 2021 American Society of Clinical Oncology (ASCO) An

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today provided the following corporate update, in line with its commitment to maintain continuing dialogue with investors and other stakeholders on the progress and development of the Company. Commercializing AC5 ® Advanced Wound System As Arch transitions to a commercialization stage

Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced that it will release fiscal fourth quarter and full year 2021 financial results on Wednesday, May 5, 2021,

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer, effective immediately

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.